Untangling the Estrogen Receptor Web

Drugs targeting estrogen action are used in the treatment of breast cancer and in the treatment of menopausal systems such as osteoporosis and hot flashes. The major problem with these therapies is that the effects of the drug are not limited to the target tissue. The common breast cancer hormone therapy tamoxifen, is anti-estrogenic in the breast but is pro-estrogenic in the uterus, leading to increased risk of uterine cancer. Another estrogen targeted drug, raloxifene, has a different tissue response profile. Our lab wants to know why these drugs have different responses in different tissues and then synthesize new drugs with better profiles for breast cancer and hormone replacement therapies. We hope that our work will lead to better treatments for breast cancer with less side effects, more effective treatments for antiestrogen-resistant breast cancer and perhaps improved therapies for menopausal symptoms

Project 1: Bioactive Estrogen and Antiestrogen Conjugates